Drug intelligence / Profile preview

VLT-015

Development stage: Phase 1
Lead developer: Valentech
Modality: Small Molecules
Administration: Oral

Overview

VLT-015 is an orally administered drug candidate developed by Valentech, primarily investigated for the treatment of schizophrenia. The drug is being studied in the context of nervous system diseases. There is no publicly available information on its precise mechanism of action or molecular target, and it does not appear to have reached advanced clinical development stages or received regulatory approval as of 2024.

Other names: VLT015VLT-015VLT 015

Beyond the preview

Go deeper on VLT-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLT-015.

Explore the full profile